254 related articles for article (PubMed ID: 35443896)
1. Solid Lipid Nanoparticles: A Potential Option for Enhancing Oral Bioavailability of Highly Soluble and Poorly Permeable (BCS Class III) Drugs.
Sri Rekha M ; Sangeetha S ; Seetha Devi A
Curr Drug Deliv; 2023; 20(3):223-236. PubMed ID: 35443896
[TBL] [Abstract][Full Text] [Related]
2. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability.
Talegaonkar S; Bhattacharyya A
AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893
[TBL] [Abstract][Full Text] [Related]
3. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery.
Teixeira MC; Carbone C; Souto EB
Prog Lipid Res; 2017 Oct; 68():1-11. PubMed ID: 28778472
[TBL] [Abstract][Full Text] [Related]
4. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
Banerjee S; Pillai J
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
[No Abstract] [Full Text] [Related]
5. Improving in vivo oral bioavailability of a poorly soluble drug: a case study on polymeric versus lipid nanoparticles.
Rassu G; Obinu A; Serri C; Piras S; Carta A; Ferraro L; Gavini E; Giunchedi P; Dalpiaz A
Drug Deliv Transl Res; 2023 Apr; 13(4):1128-1139. PubMed ID: 36509967
[TBL] [Abstract][Full Text] [Related]
6. The Solubility-Permeability Interplay for Solubility-Enabling Oral Formulations.
Nainwal N; Singh R; Jawla S; Saharan VA
Curr Drug Targets; 2019; 20(14):1434-1446. PubMed ID: 31333138
[TBL] [Abstract][Full Text] [Related]
7. Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.
Okur NÜ; Siafaka PI; Gökçe EH
Curr Pharm Biotechnol; 2021; 22(7):892-905. PubMed ID: 32753006
[TBL] [Abstract][Full Text] [Related]
8. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
9. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM
Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786
[TBL] [Abstract][Full Text] [Related]
10. Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.
Chow EC; Talattof A; Tsakalozou E; Fan J; Zhao L; Zhang X
AAPS J; 2016 Nov; 18(6):1500-1511. PubMed ID: 27520379
[TBL] [Abstract][Full Text] [Related]
11. Organogel Nanoparticles as a New Way to Improve Oral Bioavailability of Poorly Soluble Compounds.
Martin B; Garrait G; Beyssac E; Goudouneche D; Perez E; Franceschi S
Pharm Res; 2020 May; 37(6):92. PubMed ID: 32394200
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of Functionalized Polymeric Nanoparticles to Improve Intestinal Permeability of Drugs and Biological Products.
de Souza ML; de Albuquerque Wanderley Sales V; Alves LP; Dos Santos WM; de Moura Ferraz LR; de Andrade Lima GS; Dos Santos Mendes LM; Rolim LA; Neto PJR
Curr Pharm Des; 2022; 28(5):410-426. PubMed ID: 34348618
[TBL] [Abstract][Full Text] [Related]
13. BCS class IV drugs: Highly notorious candidates for formulation development.
Ghadi R; Dand N
J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
[TBL] [Abstract][Full Text] [Related]
14. Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules.
Dave VS; Gupta D; Yu M; Nguyen P; Varghese Gupta S
Drug Dev Ind Pharm; 2017 Feb; 43(2):177-189. PubMed ID: 27998192
[TBL] [Abstract][Full Text] [Related]
15. A Rundown Through Various Methods Used in the Formulation of Solid Self-Emulsifying Drug Delivery Systems (S-SEDDS).
Almeida SRD; Tippavajhala VK
AAPS PharmSciTech; 2019 Oct; 20(8):323. PubMed ID: 31654184
[TBL] [Abstract][Full Text] [Related]
16. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery.
Agüeros M; Espuelas S; Esparza I; Calleja P; Peñuelas I; Ponchel G; Irache JM
Expert Opin Drug Deliv; 2011 Jun; 8(6):721-34. PubMed ID: 21463219
[TBL] [Abstract][Full Text] [Related]
17. Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.
Papich MG; Martinez MN
AAPS J; 2015 Jul; 17(4):948-64. PubMed ID: 25916691
[TBL] [Abstract][Full Text] [Related]
18. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured Lipid Carriers- A Versatile Carrier for Oral Delivery of Lipophilic Drugs.
Patel P; Patel M
Recent Pat Nanotechnol; 2021; 15(2):154-164. PubMed ID: 32912129
[TBL] [Abstract][Full Text] [Related]
20. Analysis of five active ingredients of Er-Zhi-Wan, a traditional Chinese medicine water-honeyed pill, using the biopharmaceutics classification system.
Cao X; Li H; Wang M; Ren X; Deng Y
Biomed Chromatogr; 2020 Feb; 34(2):e4757. PubMed ID: 31755125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
